Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model

Journal of Hepatology

Volumn 38, Issue 2, 2003, Pages 215-222

  Aggarwal, Rakesh ^a   Ghoshal, Uday C ^a   Naik, Subhash R ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cost benefit analysis; Cost utility analysis; Economic analysis; Hepatitis B virus; Monte Carlo simulation; Prevention

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; ENDEMIC DISEASE; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNIZATION; INDIA; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

EID: 0037309915     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00382-3     Document Type: Article

References (37)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. Kane MA, Clements J, Hu D. Hepatitis B. In: Jamison DT, Mosley WH, Measham AR, Bobadilla J, editors. Disease control priorities in developing countries, New York: Oxford University Press, 1993. pp. 321-330.
3. Kane MA. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47-S49.
4. World Health Assembly. Resolution WHA 45.17. Immunization and vaccine quality. Geneva: World Health Assembly, 1992.
5. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 2000;19:1026-1037.
6. World Bank. The World Bank Group. Data and statistics: Country classification. Cited October 2, 2002. Available from: http://www.worldbank.org/data/countryclass/countryclass.html.
7. Thyagarajan SP, Jayaram S, Mohanavalli B. Prevalence of HBV in general population in India. In: Sarin SK, Singal AK, editors. Hepatitis B in India: problems and prevention, New Delhi: CBS, 1996. pp. 5-16.
8. Edmunds WJ. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Commun Dis Public Health 1998;1:221-228.
9. Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 1996;32:197-204.
10. Garuz R, Torrea JL, Arnal JM, Forcen T, Trinxet C, Anton F, Antonanzas F. Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 1997;15:1652-1660.
11. Wiewiora-Pilecka D. Cost-benefit analysis of the Polish hepatitis B prevention programme. Vaccine 2000;18(Suppl 1):S52-S54.
12. Ginsberg GM, Berger S, Shouval D. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bull WHO 1992;70:757-767.
13. Hall AJ, Roberston RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, Whittle H. Cost-effectiveness of hepatitis B vaccine in the Gambia. Trans R Soc Trop Med Hyg 1993;87:333-336.
14. Miller MA, McCann L. Policy analysis of the use of hepatitis B. Haemophilus influenzae type B-, Streptococcus penumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000;9:19-35.
15. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-338.
16. World Bank. The World Bank Group. Development data: Country data. Cited December 20, 2001. Available from: http://www.world-bank.org/data/countrydata/countrydata.html
17. Chotard J, Inskip HM, Hall AJ, Loik F, Mendy M, Whittle H, et al. The Gambia Hepatitis Intervention Study: Follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-768.
18. Ministry of Health and Family Welfare (MOHFW). Evaluation of routine immunization, 1997-98. New Delhi: MOHFW, 1999.
19. Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indian J Pediatr 2000;67:299-300.
20. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995;22:1863-1873.
21. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675.
22. Louis-Jacques O, Olson AD. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Ped Gastroenterol Nutr 1997;24:25-32.
23. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type B: The EUROHEP Study Group on hepatitis B virus and cirrhosis. Hepatology 1995;21:77-84.
24. DeJongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
25. D'Amico G, Marabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-475.
26. Liaw Y-F, Lin D-Y, Chen T-J, Chu C-M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235-241.
27. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-258.
28. International Institute for Population Sciences (IIPS), ORC Macro. National family health survey (NFHS-2), 1998-99: India, Mumbai: International Institute for Population Studies, 2000. pp. 178-179.
29. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-338.
30. Aoki N, Kajiyama T, Beck JR, Cone RW, Soma K, Fukui T. Decision analysis of prophylactic treatment for patients with high-risk esophageal varices. Gastrointest Endosc 2000;52:707-714.
31. Cher DJ, Lenert LA. Rapid approximation of confidence intervals for Markov process decision models: applications in decision support systems. J Am Med Inform Assoc 1994;4:301-312.
32. Aggarwal R, Naik SR. Prevention of hepatitis B infection: the appropriate strategy for India. Natl Med J India 1994;7:216-220.
33. Mittal SK. Desirability and feasibility of hepatitis B vaccine in EPI. Indian J Pediatr 2001;68(Suppl 1):561-565.
34. McMohan BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768.
35. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med 2001;7:619-624.
36. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859.
37. Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India 2002;15(6):in press.